Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin plus paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer
CTR20180356Phase 2Active
- Sponsor
- Hainan Changan International Pharmaceutical Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lobaplatin, paclitaxel in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hainan Changan International Pharmaceutical Co., Ltd.. Started Mar 2018; status: active.
02
Drugs
lobaplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20180356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180356.